10493 INTEGRASEVPA - MK-0518 INTENSIFICATION AND HDAC INHIBITION IN DEPLETION OF

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：本研究将检验以下假设：通过丙戊酸盐和强化ART联合治疗，静息CD 4 + T细胞中的HIV感染频率将随时间推移而逐渐降低。 参会人员：年龄≥ 18岁的HIV-1感染男性和女性，接受强效抗逆转录病毒治疗，定义为至少2种NRTI+至少1种PI或NNRTI，入组前24周内未发生变化。 程序（方法）：这是一项为期24周至48周的研究治疗的开放标签初探性研究。受试者必须符合所有研究入选和排除标准才能参与本研究。受试者将在研究期间继续接受当前ART治疗。 有两个步骤： 第1步：受试者将继续当前ART，并以400 mg po BID添加MK-0518。 第2步：所有患者在进入第2步后，即第24周白细胞去除术后停用VPA。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: This study will test the hypotheses that the frequency of HIV infection within resting CD4+ T cells will be progressively decreased over time by the combination of valproate and intensified ART. Participants: HIV-1 infection men and women age =18 years on potent antiretroviral therapy, defined as at least 2 NRTIs plus at least 1 PI or NNRTI, without changes in the 24 weeks immediately prior to entry. Procedures (methods): This is an open-label pilot study of 24 weeks to 48 weeks of study treatment. Participants must meet all of the study inclusion and exclusion criteria in order to participate in this study. Subjects will continue current ART for the duration of the study. There are 2 steps: Step 1: Subjects will continue current ART and add MK-0518 at 400 mg po BID. Step 2: VPA is discontinued in all patients upon entry into Step 2, after leukopheresis at week 24.